EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk

Dimitrios Paraskevis iD, Maria Gkova, Kassiani Mellou, Gerasimos Gerolymatos, Naya Psalida, Kassiani Gkolfinopoulou, Evangelia-Georgia Kostaki, Stylianos Loukides, Anastasia Kotanidou, Athanasios Skoutelis, Eleftherios Thiraios, Georgios Saroglou und 7 weitere

The Journal of Infectious Diseases · 20.12.2023 · 228 (12) · 1667-1674

DOI: 10.1093/infdis/jiad324 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 11.08.2023. Verfasst von Dimitrios Paraskevis und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hygiene, Epidemiology, and Medical Statistics, Medical School, National and Kapodistrian University of Athens. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Public Health Organization, Greece.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Using a retrospective cohort study design, we aimed to evaluate the effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who were highly vulnerable.

Methods

The impact of each drug was determined via comparisons with age-matched control groups of patients positive for SARS-CoV-2 who did not receive oral antiviral therapy.

Results

Administration of molnupiravir significantly reduced the risk of hospitalization (odds ratio [OR], 0.40; P < .001) and death (OR, 0.31; P < .001) among these patients based on data adjusted for age, previous SARS-CoV-2 infection, vaccination status, and time elapsed since the most recent vaccination. The reductions in risk were most profound among elderly patients (≥75 years old) and among those with high levels of drug adherence. Administration of nirmatrelvir/ritonavir also resulted in significant reductions in the risk of hospitalization (OR, 0.31; P < .001) and death (OR, 0.28; P < .001). Similar to molnupiravir, the impact of nirmatrelvir/ritonavir was more substantial among elderly patients and in those with high levels of drug adherence.

Conclusions

Collectively, these real-world findings suggest that although the risks of hospitalization and death due to COVID-19 have been reduced, antivirals can provide additional benefits to members of highly vulnerable patient populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19AgedHumansRitonavirSARS-CoV-2Retrospective StudiesCOVID-19 Drug TreatmentAntiviral AgentsLactamsLeucineNitrilesProlineCytidineHydroxylamines

Stichwörter der Autor:innen

COVID-19SARS-CoV-2antiviralsmolnupiravirnirmatrelvir/ritonavir

Substanzen

RitonavirAntiviral AgentsnirmatrelvirLactamsLeucineNitrilesProlinemolnupiravirCytidineHydroxylamines

Autor:innen und Institutionen

  • Department of Hygiene, Epidemiology, and Medical Statistics, Medical School, National and Kapodistrian University of Athens.
  • National Public Health Organization.
  • Second Respiratory Medicine Department, "Attikon" University Hospital, Medical School, National and Kapodistrian University of Athens.
  • First Department of Critical Care Medicine and Pulmonary Services, Evaggelismos Hospital, Medical School, National and Kapodistrian University of Athens.
  • Second Department of Medicine and Infectious Diseases, HYGEIA Hospital, Marousi.
  • National Agency for Quality Assurance in Health, Athens.

ORCID-Profile: Dimitrios Paraskevis, Elias Mossialos

Förderung

  • National Public Health Organization, Greece

Zitieren

APA

Paraskevis, D., Gkova, M., Mellou, K., Gerolymatos, G., Psalida, N., Gkolfinopoulou, K., Kostaki, E. G., Loukides, S., Kotanidou, A., Skoutelis, A., Thiraios, E., Saroglou, G., Zografopoulos, D., Filippou, D., Mossialos, E., Zaoutis, T., Gaga, M., Tsiodras, S., & Antoniadou, A. (2023). Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk. The Journal of Infectious Diseases, 228(12), 1667-1674. https://doi.org/10.1093/infdis/jiad324

Vancouver

Paraskevis D, Gkova M, Mellou K, Gerolymatos G, Psalida N, Gkolfinopoulou K, et al. Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk. The Journal of Infectious Diseases. 2023;228(12):1667-1674. doi:10.1093/infdis/jiad324

BibTeX
@article{Paraskevis2023,
  author = {Paraskevis, Dimitrios and Gkova, Maria and Mellou, Kassiani and Gerolymatos, Gerasimos and Psalida, Naya and Gkolfinopoulou, Kassiani and Kostaki, Evangelia-Georgia and Loukides, Stylianos and Kotanidou, Anastasia and Skoutelis, Athanasios and Thiraios, Eleftherios and Saroglou, Georgios and Zografopoulos, Dimitrios and Filippou, Dimitrios and Mossialos, Elias and Zaoutis, Theoklis and Gaga, Mina and Tsiodras, Sotirios and Antoniadou, Anastasia},
  title = {Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk},
  journal = {The Journal of Infectious Diseases},
  year = {2023},
  volume = {228},
  number = {12},
  pages = {1667--1674},
  doi = {10.1093/infdis/jiad324}
}
Kostenlos starten →